No correlation between aggression and platelet (3)H-paroxetine binding in obsessive-compulsive disorder patients

Inter-relationship between different platelet measures of 5-HT and their relationship to aggression in human subjects

The objective of this study was to explore the inter-relationship of three platelet measures of serotonergic function (5-HT): 5-HT Transporter Binding, 5-HT-2 Receptor Binding and 5-HT Content and to explore their inter-relationship with measures of aggression and impulsivity. 58 male subjects with personality disorder were studied. Numbers of platelet 5-HT Transporter and 5-HT-2 Receptor sites were assessed by examining the Bmax of ³H-Paroxetine Binding and the Bmax of ¹²⁵I-LSD Binding to the blood platelet; 5-HT Content was assessed by measuring the amount of 5-HT in the platelet material. Life history of aggression was assessed by Life History of Aggression. Impulsivity was assessed by the Impulsivity Scale of the Eysenck Personality Questionnaire-II. Platelet 5-HT Transporter Binding correlated with both 5-HT-2 Receptor Binding and 5-HT Content; the latter two variables did not correlate with each other. Only Platelet 5-HT Transporter binding correlated significantly with LHA Aggression. These data suggest that while Platelet 5-HT Transporter binding correlates with both 5-HT-2 Receptor Binding and with 5-HT Content, that only 5-HT Transporter Binding represents a correlate of aggression in male personality disordered subjects.

Inverse relationship between numbers of 5-HT transporter binding sites and life history of aggression and intermittent explosive disorder

The objective of this study was to determine if platelet 5-HT transporter (5-HTT) sites vary as a function of aggression, and/or impulsiveness, and differ as a function of Intermittent Explosive Disorder (IED). Accordingly, the number of platelet 5-HTT sites was assessed in 100 personality disordered (PD) individuals with varying degrees of aggressiveness. The number of platelet 5-HTT sites was assessed by examining the Bmax of H(3)-Paroxetine Binding to the blood platelet. Life history of aggression was assessed by Life History of Aggression. Impulsivity was assessed by the Barratt Impulsiveness Scale. Diagnoses of IED were made by both DSM-IV and Research Criteria. Examination of the data revealed that Bmax, but not Kd, values of Platelet H(3)-Paroxetine Binding correlated inversely with the LHA Aggression score (r=-.42 n=87, p<.001) but not with the BIS-11 Impulsivity score (r=.03, n=77, p=.777). PD subjects meeting Research Criteria for IED demonstrated a significant reduction in Bmax values for Platelet H(3)-Paroxetine Binding. These results were similar after accounting for the effect of lifetime history of depressive mood disorder on Bmax values for Platelet H(3)-Paroxetine Binding. These data indicate a significant inverse relationship between platelet 5-HTT and aggression, though not impulsivity, as a dimensional variable in personality disordered individuals. Results from the examination of IED as a categorical aggression variable suggest that Research, rather than DSM-IV, criteria better identify individuals with reduced numbers of platelet 5-HTT sites.

Plasma serotonin levels in young violent offenders: Aggressive responding and personality correlates

70 young male violent offenders and 30 normal controls in Hunan, China were interviewed and assessed by the Minnesota Multiphasic Personality Inventory (MMPI), Point Subtraction Aggression Paradigm (PSAP) and plasma serotonin (5-HT) level. Compared to the normal controls, the violent offenders had significantly higher plasma 5-HT levels; higher scores on the MMPI subscale Pd (P < 0.01), Pa (P < 0.05); and higher PSAP-B responding and lower PSAP-C responding (P < 0.05). There was a positive correlation between the MMPI Pd score and the PSAP B response, but no significant correlation was found between Pd score and plasma 5-HT level, or between PSAP B response and plasma 5-HT level. Our data suggest that the young violent offenders are more aggressive than the normal control. But this study did not demonstrate that the plasma 5-HT level had a correlation with the PSAP aggressive response. The relationship between the aggressiveness and impulsivity in the violent behavior needs further study.

Impaired platelet [3H]paroxetine binding in female patients with borderline personality disorder

RATIONALE

There have been few studies of platelet paroxetine binding in borderline personality disorder (BPD).

OBJECTIVE

Our aim was to determine whether female BPD subjects show abnormalities in platelet paroxetine binding.

METHODS

Twenty-one female BPD subjects and 16 age- and gender-matched normal control subjects were assessed using the following: (1) Diagnostic Interview for Borderlines, Revised, (2) Diagnostic Assessment for Personality Pathology: Brief Questionnaire, and (3) Barratt Impulsivity Scale. Platelets were collected and assayed for platelet paroxetine binding.

RESULTS

Bmax was lower in the BPD group (p < 0.0001), but differences in Kd only reached a trend level. There were no associations with trait dimensions independent of diagnosis.

CONCLUSIONS

Reduced platelet paroxetine binding in female BPD patients may reflect presynaptic serotonin dysfunction.

Platelet serotonergic predictors of clinical improvement in obsessive compulsive disorder

OBJECTIVE

Serotonin reuptake inhibitors (SRIs) are the most efficient pharmacological treatment of obsessive-compulsive disorders (OCD). Previous studies have suggested that some peripheral serotonergic parameters can be used to predict the clinical outcome of the treatment of OCD patients with SRIs. We tried to identify further peripheral serotonergic parameters that could help predict the clinical outcome of SRI treatment in a sample of patients with OCD.

METHODS

We compared 19 OCD patients before and after 8 weeks of SRI treatment with 19 sex-matched and age-matched controls. We assessed clinical improvement and whole-blood serotonin (5-HT) concentration, platelet 5-HT transporter (5-HTT) and 5-HT2A receptor binding characteristics and platelet IP3 content.

RESULTS

Before treatment, OCD patients had higher platelet IP3 content and fewer 5-HTT binding sites than the controls. Treatment with SRIs further lowered the number of 5-HTT binding sites, normalized platelet IP3 contents, and lowered the number of platelet 5-HT2A binding sites and whole-blood 5-HT concentrations below control values. The patients who improved most following SRI treatment had higher whole-blood 5-HT concentrations before treatment.

CONCLUSION

Our results confirm that whole-blood 5-HT concentration is a predictor for clinical improvement and indicate that abnormal intracellular mechanisms may be involved in OCD patients, in particular, the overstimulation of the phosphoinositide signaling system.